Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Achieve Life Sciences Inc (ACHV)
NASDAQ:ACHV
RESEARCH TOOLSreports
Holding ACHV?
Track your performance easily
Earnings Data
Report Date
Mar 13, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.34Last Year’s EPS
-$0.26Same Quarter Last Year
Strong Buy
Based on 6 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 07, 2024
|% Change Since: -26.20%
|Next Earnings Date:Mar 13, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress with the breakthrough therapy designation for vaping cessation, successful enrollment in the ORCA-OL trial, and a strong cash position supporting future growth. However, the increased net loss and executive restructure costs were notable challenges.Company Guidance
During Achieve Life Sciences' third-quarter 2024 earnings call, the company provided comprehensive guidance on multiple fronts. They emphasized their upcoming New Drug Application (NDA) submission for cytisinicline, a smoking cessation treatment, targeted for Q2 2025. Achieve highlighted a target population of over 40 million Americans with nicotine dependence and discussed their strategic shift towards commercialization, including digital-first strategies to reach primary care physicians. The ongoing ORCA-OL safety trial enrolled 479 participants across 29 sites, completing enrollment ahead of schedule, and is integral for the NDA. Financially, Achieve reported a net loss of $12.5 million for the quarter, with cash reserves of $42.9 million, projecting liquidity into the second half of 2025. The company also secured a $20 million refinancing agreement with Silicon Valley Bank. They are exploring the potential for vaping cessation, particularly in adolescents, and addressing nicotine dependence from tobacco pouches, while maintaining focus on their core smoking cessation strategy.Breakthrough Therapy Designation
FDA granted breakthrough therapy designation for cytisinicline for vaping cessation, providing access to an FDA cross-disciplinary project management team.
ORCA-OL Safety Trial Enrollment
The ORCA-OL safety trial for cytisinicline completed enrollment ahead of expectations with 479 participants across 29 trial sites in the United States.
Strong Cash Position
As of September 30, 2024, Achieve Life Sciences had $42.9 million in cash, cash equivalents, restricted cash, and short-term investments, providing runway into the second half of 2025.
Digital-First Commercial Strategy
Achieve is adopting an innovative digital-first strategy to efficiently target primary care physicians and patients for the launch of cytisinicline.
Successful Debt Refinancing
Achieve completed a debt refinancing agreement with SVB, providing up to $20 million in availability, divided into three tranches.
---
ACHV Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ACHV Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 07, 2024 | $5.00 | $4.63 | -7.40% |
| Aug 13, 2024 | $4.36 | $4.38 | +0.46% |
| May 09, 2024 | $4.53 | $4.61 | +1.77% |
| Mar 28, 2024 | $4.54 | $4.58 | +0.88% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Achieve Life Sciences Inc (ACHV) report earnings?
Achieve Life Sciences Inc (ACHV) is schdueled to report earning on Mar 13, 2025, TBA Not Confirmed.
What is Achieve Life Sciences Inc (ACHV) earnings time?
Achieve Life Sciences Inc (ACHV) earnings time is at Mar 13, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ACHV EPS forecast?
ACHV EPS forecast for the fiscal quarter 2024 (Q4) is -$0.34.
---